Trial Profile
Phase II Study of Osimertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Sep 2021 Status changed from active, no longer recruiting to completed.
- 31 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2018 New trial record